Toward Single-Time-Point Image-Based Dosimetry of ¹⁷⁷Lu-PSMA-617 Therapy.

ABSTRACT: Radiopharmaceutical therapies (RPTs) with ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) ligands have demonstrated promising results for the treatment of metastatic castration-resistant prostate cancer. The lack of absorbed-dose-effect relationships currently prevents patient-specific activity personalization. To ease the implementation of dosimetry in the routine clinical workflow for RPT, simplified methods such as single-time-point (STP) instead of multiple-time-point (MTP) imaging protocols are required. This work aimed at assessing differences in the time-integrated activity (TIA) of STP versus MTP image-based dosimetry for ¹⁷⁷Lu-PSMA-617 therapy. Methods: Twenty metastatic castration-resistant prostate cancer patients with MTP quantitative ¹⁷⁷

SUBMITTER: Brosch-Lenz J 

PROVIDER: S-EPMC10152120 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature